Usually, when people recount the successes of the pharmaceutical industry, they tend to focus only on the scientific creativity, groundbreaking therapies, and the overall transformative nature of those things. However, behind each successful launch of an innovative new drug, there’s always an extremely complex operational framework that determines how efficiently, compliantly, and competitively the potential new drug can actually get to patients.
Because clinical trials continue to grow into entirely global enterprises, pharmaceutical organizations are facing additional challenges in trying to manage their development timelines while also navigating the regulatory requirements, supply chain disruptions, issues pertaining to intellectual property, and constantly evolving marketplace demands. In today’s world, the success or failure of any pharmaceutical enterprise is no longer based solely upon the scientific merits of the drug being developed. Instead, it is now critical for these organizations to create a cohesive, comprehensive ecosystem that connects the clinical supply chain, the licensing of the drug, the manufacturing of the drug, and the commercial readiness of the drug.
Perhaps the largest shift currently taking place in the way that new drugs are being developed is the evolution from a disjointed operational capability to an interconnected strategic partnership between all of the various operational segments of drug development. The various parties involved in the development of a new pharmaceutical product have actually begun to recognize that the aspects of clinical supply chain planning, manufacturing, regulatory compliance, and market access must work collaboratively and together right from the beginning of the drug development process.
The importance of specialized partners has increased dramatically in response to this structural change, and there are many different types of specialized partners, including pharma contract companies, experts in comparator sourcing, experienced contract manufacturing consultants and companies providing comparator drug and pharma licensing services.
Through the following blog, we will illustrate the extent to which integrated development strategies are dramatically changing the face of the pharmaceutical industry, and how companies that align their sourcing, licensing, and manufacturing functions from the very beginning will create a significant advantage over their competition.
The New Reality of Drug Development
The complexity of drug development is increasing dramatically. Clinical trials now include multiple countries, diverse patient populations and more stringent requirements for strong evidence regarding safety, effectiveness and product comparison.
Pharmaceutical organisations are confronted with challenges:
- Increasing costs of development
- Longer regulatory review periods
- Uncertainty in global supply chain operations
- Patent and exclusivity considerations
- Compliance with country-specific requirements
- Increased competition from innovative treatments
- These challenges make operational efficiency essential to success.
Many factors can add unexpected delays to study start-up, regulatory submissions or commercial launch of drug products or clinical studies, including delays in receiving reference products, establishing manufacturing capacity or meeting regulatory requirements. A single delay can produce a domino effect, resulting in delays to every stage of product development.
As a result, modern pharmaceutical organisations need to have an integrated view of the entire product development process.
Why Operational Integration Is a Competitive Advantage?
For the most part, clinical teams, regulatory groups, manufacturing departments, and commercial teams historically operated independently.
Although this structure functioned in simpler development environments, the current global pharmaceutical ecosystem has a higher demand for collaboration.
There are numerous advantages to integrated development strategies:
Faster Decisions
Early collaboration among sourcing/manufacturing/licensing groups assists organisations in identifying problems prior to them becoming a significant barrier to success.
Decreased Development Risks
Integrating functions through cross-functional planning can help organisations reduce regulatory errors, supply chain issues and operational inefficiencies.
Better Cost Management
By coordinating plans, organisations can eliminate duplicate work efforts and mitigate costly last-minute adjustments.
Enhanced Regulatory Readiness
By integrating documentation, compliance requirements, and submission strategies, integrated teams will be better positioned to align all their teams in preparation for the regulatory burden.
Improved Market Readiness
Development decisions made during clinical phases will directly or indirectly impact future market access and commercial possibilities.
Companies that adopt integration are progressively outperforming their competitors who continue to operate in a siloed manner.
Expanding Role of Comparator Products in Global Clinical Research
Comparator drugs play a critical role in modern clinical research.
Mny clinical trials require investigational drugs to be compared with an active drug instead of a placebo. This provides meaningful data on the effectiveness, safety, and clinical value of the products being evaluated.
Obtaining comparator drugs is often quite difficult.
Pharmaceutical companies are often challenged by various factors to successfully obtain comparator drugs, including:
- Limited availability of the comparator drugs
- Geographic limitations
- Regulatory regulations
- Logistics of temperature-controlled transportation
- Authentication of products
- Labelling and packaging requirements.
These challenges create the need for a strategic approach to comparator sourcing, which has increased in importance.
Acquisition of comparators has become a key function that will impact the success of the clinical trial. Organizations should ensure that comparators are of high quality and delivered on time in sufficient quantities to meet the study’s requirements.
If an organization does not have a sound sourcing strategy, even the best clinical program can encounter significant delays.
How Globalization Is Reshaping Clinical Supply Strategies
Globalization has led not only to new opportunities for clinical research but also to new challenges.
Today’s clinical trials often involve multiple continents and require product access from different regulatory jurisdictions.
Additionally, organizations must take into account:
- Regional approval
- Country-specific distribution
- Import/export regulations
- Customs clearance
- Local labeling expectations
- Storage/transportation standards
Because of these issues, organizations require supply chains that are agile, resilient and coordinated.
Sourcing specialists add significant value when helping sponsors navigate these complexities. Sourcing specialists help sponsors navigate complexities that would delay studies due to their knowledge of international regulations and market dynamics.
The outcome is a clinical development process that can be completed in a more predictable manner, with fewer disruptions.
The Importance of Licensing Strategy
While licensing is typically viewed as a commercialization and market expansion strategy for many companies, as forward-thinking companies increasingly consider licensing more during the development phase of their products, they will benefit from:
Improved Market Access Planning
Knowing what licensing opportunities lie ahead allows companies to make investment choices in development based on priority.
Improved Risk Management
Pharma licensing service reviews will often uncover potential risks regarding intellectual property and/or regulatory challenges.
Increased Opportunities for Partnerships
Engaging with potential partners earlier creates collaborative and expansion opportunities.
Improved Commercial Forecasting
An organization has greater visibility regarding potential future revenues and overall market potential.
This is the transformational change that is pushing companies to think about long-term growth.
The Growing Importance of Comparator Drug & Pharma Licensing Service Solutions
With global pharmaceutical product development becoming increasingly common, there is continued demand for specialized comparator drug and pharma licensing service providers.
These services assist companies with their critical requirements, including:
- Access points to product distribution.
- Evaluation of licensing terms.
- Assistance with the preparation of regulatory documentation.
- Considerations for intellectual property issues.
- Plans for market entry.
- Facilitate establishing partnerships.
Instead of treating licensing as a separate function, companies are now incorporating licensing into the larger development strategy, which allows them to improve overall efficiency and develop additional opportunities for future company growth.
Companies that understand the implications of licensing earlier than later will usually have better chances of successfully commercializing their products.
Final Thoughts
Pharmaceutical companies will increasingly need to integrate research and operational processes to develop drugs whose benefits will ultimately depend upon the ability to manufacture and supply those drugs effectively. Clinical viability alone will not guarantee commercial success anymore. Companies will need to create an infrastructure that ties together:
- Manufacturing
- Contracting
- Supply Chain Management
- Regulatory Planning
- Commercialization Strategies
This ties back into the fact that pharmaceutical contract manufacturing consultant are continuing to grow their importance in the industry as they provide significant amounts of expertise and experience to assist companies with comparator sourcing.
Pharmaceutical companies have realized that collaboration, foresight and integration are crucial components to successful drug development. By incorporating these elements into their operations, companies can reduce the risks associated with drug development, accelerate the time it takes to develop drugs, enhance compliance with regulatory requirements, and improve their success at bringing novel drugs to market.
As the pharmaceutical landscape becomes increasingly global and competitive, companies that succeed will be those that examine their sourcing, licensing and manufacturing as the three main components of a unified strategy for growth and innovation over the long haul.